Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP1/AMPK pathway

Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1282-1291. doi: 10.1016/j.bbadis.2017.03.019. Epub 2017 Mar 29.

Abstract

Obesity is often accompanied by decreases in the proportion of skeletal muscle slow-twitch fibers and insulin sensitivity. Increased plasma non-esterified fatty acids (NEFA) levels are responsible for obesity-associated insulin resistance. Palmitate, one of the most elevated plasma NEFA in obesity, has been recognized as the principle inducer of insulin resistance. The present study showed that increased plasma NEFA levels were negatively linked to slow-twitch fiber proportion and insulin sensitivity, while slow-twitch fiber proportion was positively correlated to insulin sensitivity in high fat diet (HFD)-fed and ob/ob mice. Dihydromyricetin (DHM) intervention increased slow-twitch fiber proportion and improved insulin resistance. In cultured C2C12 myotubes, palmitate treatment resulted in decrease of slow-twitch fiber specific Myh7 expression and insulin resistance, concomitant with folliculin (FLCN) and folliculin-interacting protein 1 (FNIP1) expression increase, AMP-activated protein kinase (AMPK) inactivation and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) expression decrease. Those palmitate-induced effects could be blocked by knock-down of FLCN expression or DHM intervention. Meanwhile, the protective effects of DHM were alleviated by over-expression of FLCN. In addition, the changes in AMPK activity and expression of FLCN and FNIP1 in vivo were consistent with those occurring in vitro. These findings suggest that DHM treatment prevents palmitate-induced slow-twitch fibers decrease partially via FLCN-FNIP1-AMPK pathway thereby improving insulin resistance in obesity.

Keywords: AMPK; Dihydromyricetin; FLCN; FNIP1; Slow fibers.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Carrier Proteins / biosynthesis*
  • Dietary Fats / adverse effects
  • Dietary Fats / pharmacology
  • Flavonols / pharmacology*
  • Gene Expression Regulation / drug effects
  • Insulin Resistance*
  • Male
  • Mice
  • Muscle Fibers, Slow-Twitch / metabolism*
  • Muscle Fibers, Slow-Twitch / pathology
  • Obesity
  • Proto-Oncogene Proteins / biosynthesis*
  • Signal Transduction*
  • Tumor Suppressor Proteins / biosynthesis*

Substances

  • Bhd protein, mouse
  • Carrier Proteins
  • Dietary Fats
  • FNIP1 protein, mouse
  • Flavonols
  • Proto-Oncogene Proteins
  • Tumor Suppressor Proteins
  • AMP-Activated Protein Kinases
  • dihydromyricetin